Researcher
Herlinde Dumez
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Oncology (Division)
Member
From1 Oct 2005 → Today
Publications
31 - 40 of 64
- Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity(2015)
Authors: Herlinde Dumez, Kathleen Forceville, Patrick Schöffski
Pages: 611 - 20 - Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity(2015)
Authors: Ahmad Awada, Herlinde Dumez, Philippe G Aftimos, Jo Costermans, Sylvie Bartholomeus, Kathleen Forceville, Thierry Berghmans, Marie-Anne Meeus, Jessica Cescutti, Gerd Munzert, et al.
Pages: 611 - 20 - Incidence of bowel wall oedema on computed tomography exams and association with diarrhoea in renal cell carcinoma patients treated with sunitinib(2015)
Authors: Filip Claus, Herlinde Dumez, Frederik De Keyzer, Evelyne Lerut, Hendrik Van Poppel, Benoit Beuselinck
Pages: 375 - 379 - Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial(2015)
Authors: Cora N Sternberg, Iwona Skoneczna, J Martijn Kerst, Peter Albers, Sophie D Fossa, Mads Agerbaek, Herlinde Dumez, Maria de Santis, Christine Théodore, Michael G Leahy, et al.
Pages: 76 - 86 - Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial(2015)
Authors: Herlinde Dumez
Pages: 76 - 86 - Sarcomatoid Dedifferentiation in Metastatic Clear Cell Renal Cell Carcinoma and Outcome on Treatment With Anti-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Retrospective Analysis(2014)
Authors: Benoit Beuselinck, Evelyne Lerut, Herlinde Dumez, Joost Berkers, Hendrik Van Poppel, Steven Joniau, Raymond Oyen, Robert Paridaens, Patrick Schöffski
Pages: E205 - E214 - Prognostic Impact of Baseline Serum C-Reactive Protein in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib(2014)
Authors: Benoit Beuselinck, Hendrik Van Poppel, Steven Joniau, Evelyne Lerut, Herlinde Dumez, Robert Paridaens, Ben Van Calster, Patrick Schöffski
Pages: 81 - 9 - What is new in metastatic castrationresistant prostate cancer?(2014)
Authors: Herlinde Dumez
Pages: 570 - 576 - 18F-MK-9470 PET imaging of the type 1 cannabinoid receptor in prostate carcinoma: a pilot study(2013)
Authors: Michel Koole, Cindy Casteels, Guy Bormans, Filip Claus, Evelyne Lerut, Hendrik Van Poppel, Steven Joniau, Herlinde Dumez, Karin Haustermans, Luc Mortelmans, et al.
Pages: 59 - Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors(2013)
Authors: Herlinde Dumez, Patrick Schöffski
Pages: 734 - 741